AbbVie Inc. (ABBV)
NYSE: ABBV · IEX Real-Time Price · USD
172.32
+1.18 (0.69%)
At close: Jul 19, 2024, 4:00 PM
172.26
-0.06 (-0.03%)
Pre-market: Jul 22, 2024, 5:30 AM EDT
AbbVie Revenue
AbbVie had revenue of $54.40B in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $12.31B with 0.70% year-over-year growth. In the year 2023, AbbVie had annual revenue of $54.32B.
Revenue (ttm)
$54.40B
Revenue Growth
-4.12%
P/S Ratio
5.59
Revenue / Employee
$1,088,060
Employees
50,000
Market Cap
304.29B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
Dec 31, 2009 | 14.21B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Eli Lilly | 35.93B |
Novo Nordisk | 35.35B |
ABBV News
- 9 days ago - AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis - PRNewsWire
- 9 days ago - Alzamend Neuro Announces Reverse Stock Split - Business Wire
- 11 days ago - AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer - PRNewsWire
- 18 days ago - AbbVie cuts 2024 profit forecast on acquisition-related expenses - Reuters
- 19 days ago - AbbVie to Host Second-Quarter 2024 Earnings Conference Call - PRNewsWire
- 20 days ago - Robert A. Michael Assumes Role as AbbVie Chief Executive Officer - PRNewsWire
- 24 days ago - AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma - PRNewsWire
- 24 days ago - AbbVie Acquires Celsius Therapeutics - PRNewsWire